Rationale and design of the prevention of cerebrovascular and cardiovascular events of ischemic origin with Terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study

• Verfasst von: Hennerici, Michael G. [VerfasserIn]
• Titel: Rationale and design of the prevention of cerebrovascular and cardiovascular events of ischemic origin with Terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study
• Verf.angabe: Michael G. Hennerici on behalf of the PERFORM study investigators (University of Heidelberg, Mannheim, Germany)
• E-Jahr: 2009
• Jahr: May 14, 2009
• Umfang: 5 S.
• Fussnoten: Gesehen am 17.03.2021
• Titel Quelle: Enthalten in: Cerebrovascular diseases
• Ort Quelle: Basel : Karger, 1991
• Jahr Quelle: 2009
• Band/Heft Quelle: 27(2009), Suppl. 3, Seite 28-32
• ISSN Quelle: 1421-9786
• DOI: doi:10.1159/000209263
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1751633896

Abstract

Background: One of the leading causes of mortality worldwide is ischemic stroke, which is a major contributor to neurological disability and dementia. Terutroban is a specific thromboxane A receptor antagonist with antithrombotic, antivasoconstrictive, and antiatherosclerotic properties, which make it a promising tool for secondary prevention of ischemic stroke. Methods and Results: The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study is an international, multicenter, randomized, double-blind, parallel-group study in patients aged ≥55 years who have suffered ischemic strokes (<3 months) or transient ischemic attacks (<8 days), and who are stable at inclusion with no intracranial hemorrhage or nonischemic neurological diseases. Patients are randomly allocated to terutroban (30 mg/day) or aspirin (100 mg/day). The primary efficacy end point is a composite of ischemic stroke (fatal or nonfatal), myocardial infarction (fatal or nonfatal), or other vascular death (excluding hemorrhagic death of any origin). Safety is evaluated by assessing hemorrhagic events. The first patient was randomized in February 2006 and more than 19,000 patients will be included. Conclusions: The PERFORM Study will explore the benefits of terutroban in secondary prevention of ischemic stroke. The study results are expected in 2011.